Kenvue highlights dividend profile, analysts map out KVUE shares on the NYSE

Kenvue, the consumer health group spun off from Johnson & Johnson and listed on the NYSE under KVUE, remains in focus for its dividend profile and analyst coverage, with consensus targets and ratings framing the current picture for the shares.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 19:01.

Kenvue (US49177J1025), the consumer health company carved out of Johnson & Johnson and listed on the NYSE under the ticker KVUE, stays on investor screens for its combination of dividend yield and brand portfolio. Analyst consensus data and current valuation metrics frame how the market prices the stock, according to recent coverage from MarketWatch and other research aggregators.

What analysts say about Kenvue

On the NYSE, Kenvue trades alongside peers like Procter & Gamble and Colgate-Palmolive, which gives analysts a clear consumer-staples reference set for margins, cash flow and payout ratios. Consensus data compiled by MarketWatch and other financial portals shows a mix of Buy and Hold ratings on KVUE, with only a minority of analysts currently recommending Sell.

Price targets center around the high-teens to low-20s US dollars per share, implying limited but positive expected upside from the latest trading range. Several houses highlight Kenvue’s defensive profile, underpinned by over-the-counter medicines and personal-care brands, and see the company’s dividend as a key component of total return in a lower-growth consumer environment.

Focus on valuation and dividend

Valuation metrics published by TradingKey and similar platforms place Kenvue on earnings and cash-flow multiples broadly in line with large-cap consumer-staples peers. The stock’s dividend yield screens as competitive compared with household-product groups such as Procter & Gamble, reflecting the market’s expectation of a steady, if unspectacular, growth path for consumer health.

Analysts also monitor how Kenvue balances shareholder distributions with investment in marketing, innovation and emerging-market expansion. The ability to defend brand equity and pricing power in categories like pain relief, cough and cold, and skin care is frequently cited as a determinant of whether KVUE can sustain its current valuation relative to listed peers.

How Kenvue makes its money

Kenvue generates revenue primarily from over-the-counter medicines, self-care and beauty products sold globally through pharmacies, supermarkets and online channels. A prominent example is Tylenol, a well-known pain-relief brand that sits at the center of the group’s consumer health portfolio and competes with products from Procter & Gamble and Haleon.

Where the KVUE shares trade

The Kenvue shares (US49177J1025) trade on the NYSE under the ticker KVUE, with the last observable price information in public quote data placing the stock in the high-teens US-dollar range per share; this level and the corresponding market capitalization reflect the most recently available trading data for KVUE as of the current session.

Key data on the Kenvue shares

• Company: Kenvue Inc.
• ISIN: US49177J1025
• WKN: A3E5ZV
• Ticker: KVUE
• Trading venue: NYSE
• Price (as of latest available session): high-teens range USD
• Market cap: tens of billions USD (as of latest available data)
• Sector / industry: Consumer Staples / Consumer Health
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article is for informational purposes only and does not constitute investment advice or an invitation to buy or sell securities.